The trading session has ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, … Continue reading Biotech News: Top Stocks Review For The Week

Shares of MannKind Corp. have been on a wild ride over the past year. Most of this volatility is the result of emotionally-charged retail investors pushing the stock past realistic valuation levels. This stock serves as another glaring example as to why it’s generally a bad idea to follow the crowd when investing in biotech stocks. MannKind Corp. (NASDAQ MNKD) is the latest cult biotech … Continue reading Active Biotech Stock: A Look at Mannkind Corp

Bargain hunters should focus on biotechs since momentum is clearly on their side. On Wednesday, stocks closed higher, led by the small- and mid-cap sectors. The Nasdaq led all other indices, up 1%, while the S&P 500 rose 0.7% with 7 of 10 sectors advancing, and the Dow industrials gained 0.6%. Retail sales for July were flat, but rather than this being interpreted as a … Continue reading Biotech Stocks Are A Bargain in Today’s Market

Extending its association with Carmel, IN-based software solutions provider – Clinical Architecture, Allscripts Healthcare Solutions, Inc. (MDRX) contracted to integrate the former’s comprehensive terminology management system, Symedical, with its dbMotion interoperability platform to streamline vocabulary mapping. By incorporating Symedical, Allscripts intends to provide its clients with efficient and enhanced mapping tools and improved vocabulary distribution. This would allow the clients to achieve health information exchange … Continue reading Biotech News: Allscripts Healthcare & Clinical Architecture Extend Critical Alliance

Jazz Pharmaceuticals (JAZZ) shares climbed 6.97% after the company announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc. The deal is expected to close in the third quarter of 2014. Sigma-Tau held the rights to defibrotide on the basis of an agreement with Gentium, which was acquired by Jazz Pharma earlier this year. Jazz Pharma markets … Continue reading Biotech Stock News: Jazz Pharma Shares Go Up Due to Defibrotide Buy